Functional variant (-1304T>G) in the MKK4 promoter is associated with decreased risk of acute myeloid leukemia in a southern Chinese population

Cancer Science

Volumn 102, Issue 8, 2011, Pages 1462-1468

  Jiang, Lan ^a   Zhou, Ping ^b   Sun, Aining ^a   Zheng, Jian ^a   Liu, Bin ^c   You, Yonghe ^a   Zhang, Chun ^b   Wu, Depei ^a   Zhou, Yifeng ^a  

^a SOOCHOW UNIVERSITY   (China)

^b NANTONG UNIVERSITY   (China)

^c Guangzhou No 12 Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE KINASE 4;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CASE CONTROL STUDY; CHINESE; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; REPORTER GENE; TRANSIENT TRANSFECTION;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETICS, POPULATION; GENOTYPE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MAP KINASE KINASE 4; MAP KINASE SIGNALING SYSTEM; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; RISK;

EID: 80955179981     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.01965.x     Document Type: Article

References (32)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002; 52: 23-47.
2. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001; 51: 15-36.
3. Sanz GF, Sanz MA, Vallespi T et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood 1989; 74: 395-408.
4. Le Beau MM, Albain KS, Larson RA et al. Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7. J Clin Oncol 1986; 4: 325-45.
5. Thirman MJ, Gill HJ, Burnett RC et al. Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations. N Engl J Med 1993; 329: 909-14.
6. Gunz FW, Veale AM. Leukemia in close relatives: accident or predisposition? J Natl Cancer Inst 1969; 42: 517-24.
7. Evans DI, Steward JK. Down's syndrome and leukaemia (Abstract). Lancet 1972; 2: 1322.
8. Wei Y, Wang L, Lan P et al. The association between -1304T>G polymorphism in the promoter of MKK4 gene and the risk of sporadic colorectal cancer in southern Chinese population. Int J Cancer 2009; 125: 1876-83.
9. Cuenda A. Mitogen-activated protein kinase kinase 4 (MKK4). Int J Biochem Cell Biol 2000; 32: 581-7.
10. Chae KS, Ryu BK, Lee MG, Byun DS, Chi SG. Expression and mutation analyses of MKK4, a candidate tumour suppressor gene encoded by chromosome 17p, in human gastric adenocarcinoma. Eur J Cancer 2002; 38: 2048-57.
11. Schaeffer HJ, Weber MJ. Mitogen-activated protein kinases: specific messages from ubiquitous messengers. Mol Cell Biol 1999; 19: 2435-44.
12. Teng DH, Perry WL 3rd, Hogan JK et al. Human mitogen-activated protein kinase kinase 4 as a candidate tumor suppressor. Cancer Res 1997; 57: 4177-82.
13. Ip YT, Davis RJ. Signal transduction by the c-Jun N-terminal kinase (JNK): from inflammation to development. Curr Opin Cell Biol 1998; 10: 205-19.
14. Su GH, Hilgers W, Shekher MC et al. Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor suppressor gene. Cancer Res 1998; 58: 2339-42.
15. Jiang L, Zhang C, Li Y et al. A non-synonymous polymorphism Thr115Met in the EpCAM gene is associated with an increased risk of breast cancer in Chinese population. Breast Cancer Res Treat 2011; 126: 487-95.
16. Jiang L, Liang J, Jiang M et al. Functional polymorphisms in the NBS1 gene and acute lymphoblastic leukemia susceptibility in a Chinese population. Eur J Haematol 2011; 86: 199-205.
17. Lehmann U, Kreipe H. Real-time PCR analysis of DNA and RNA extracted from formalin-fixed and paraffin-embedded biopsies. Methods 2001; 25: 409-18.
18. Ganiatsas S, Kwee L, Fujiwara Y et al. SEK1 deficiency reveals mitogen-activated protein kinase cascade crossregulation and leads to abnormal hepatogenesis. Proc Natl Acad Sci USA 1998; 95: 6881-6.
19. Spillman MA, Lacy J, Murphy SK et al. Regulation of the metastasis suppressor gene MKK4 in ovarian cancer. Gynecol Oncol 2007; 105: 312-20.
20. 2-terminal kinase kinase 1 protein expression is subject to translational regulation in prostate cancer cell lines. Mol Cancer Res 2008; 6: 501-8.
21. Cunningham SC, Kamangar F, Kim MP et al. MKK4 status predicts survival after resection of gastric adenocarcinoma. Arch Surg 2006; 141: 1095-9.
22. Wang L, Pan Y, Dai JL. Evidence of MKK4 pro-oncogenic activity in breast and pancreatic tumors. Oncogene 2004; 23: 5978-85.
23. Cunningham SC, Gallmeier E, Hucl T et al. Targeted deletion of MKK4 in cancer cells: a detrimental phenotype manifests as decreased experimental metastasis and suggests a counterweight to the evolution of tumor-suppressor loss. Cancer Res 2006; 66: 5560-4.
24. Huang C, Huang K, Wang C et al. Overexpression of mitogen-activated protein kinase kinase 4 and nuclear factor-kappaB in laryngeal squamous cell carcinoma: a potential indicator for poor prognosis. Oncol Rep 2009; 22: 89-95.
25. Finegan KG, Tournier C. The mitogen-activated protein kinase kinase 4 has a pro-oncogenic role in skin cancer. Cancer Res 2010; 70: 5797-806.
26. Platanias LC. Map kinase signaling pathways and hematologic malignancies. Blood 2003; 101: 4667-79.
27. Cripe LD, Gelfanov VM, Smith EA et al. Role for c-jun N-terminal kinase in treatment-refractory acute myeloid leukemia (AML): signaling to multidrug-efflux and hyperproliferation. Leukemia 2002; 16: 799-812.
28. Alsayed Y, Uddin S, Mahmud N et al. Activation of Rac1 and the p38 mitogen-activated protein kinase pathway in response to all-trans-retinoic acid. J Biol Chem 2001; 276: 4012-9.
29. Miranda MB, McGuire TF, Johnson DE. Importance of MEK-1/-2 signaling in monocytic and granulocytic differentiation of myeloid cell lines. Leukemia 2002; 16: 683-92.
30. Yen A, Roberson MS, Varvayanis S, Lee AT. Retinoic acid induced mitogen-activated protein (MAP)/extracellular signal-regulated kinase (ERK) kinase-dependent MAP kinase activation needed to elicit HL-60 cell differentiation and growth arrest. Cancer Res 1998; 58: 3163-72.
31. Srinivasa SP, Doshi PD. Extracellular signal-regulated kinase and p38 mitogen-activated protein kinase pathways cooperate in mediating cytokine-induced proliferation of a leukemic cell line. Leukemia 2002; 16: 244-53.
32. Liu B, Chen D, Yang L et al. A functional variant (-1304T>G) in the MKK4 promoter contributes to a decreased risk of lung cancer by increasing the promoter activity. Carcinogenesis 2010; 31: 1405-11.